when

Zero

Safety

would

<h2 id="key-highlights">Key Highlights</h2>
<ul>
 <li>ALPHA3 trial demonstrated 58.3% MRD negativity in cema-cel patients compared to just 16.7% in the observation group</li>
 <li>Zero instances of cytokine release syndrome or neurotoxicity reported among treated participants</li>
 <li>Baird analysts upgraded their price target from $7.00 to $9.00 while maintaining Outperform status</li>
 <li>Probability of success for the therapy program increased to 70% according to Baird’s assessment</li>
 <li>Shares climbed to $3.87 from $2.91, marking approximately 99% gains year-to-date</li>
</ul>
Shares of Allogene Therapeutics experienced a dramatic rally exceeding 41% on April 13, 2026, following the disclosure of encouraging interim results from the company’s crucial Phase 2 ALPHA3 clinical study examining cemacabtagene ansegedleucel (cema-cel) in patients diagnosed with high-risk large B-cell lymphoma.
<a href="https://knockoutstocks.com/stock/ALLO" rel="noopener noreferrer nofollow"> <img src="https://knockoutstocks.com/api/stocks/ALLO/embed" alt="ALLO Stock Card"> Allogene Therapeutics, Inc., ALLO </a>
The released information originated from an interim futility analysis conducted on the trial. Within the initial cohort of 24 randomized participants, 58.3% receiving cema-cel treatment successfully achieved minimal residual disease (MRD) negativity. By contrast, the observation group saw merely 16.7% achieve this benchmark — representing a substantial 41.6 percentage point advantage.
Researchers are utilizing Natera’s investigational CLARITY MRD assay to detect high-risk patients prior to observable clinical relapse. The study positions cema-cel as a first-line consolidation treatment option, which would represent an earlier intervention point than most existing CAR T therapeutic strategies.
<h2 id="remarkable-safety-results-generate-buzz">Remarkable Safety Results Generate Buzz</h2>
The trial’s safety outcomes proved equally compelling as the effectiveness data. Remarkably, no treated participants developed cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome — two complications frequently linked with CAR T cellular therapies.
Additionally, zero treatment-related serious adverse events were documented. Such a clean safety profile stands out significantly within this therapeutic category, prompting Baird analysts to highlight it as a key distinguishing characteristic when evaluating cema-cel against second-line autologous CAR T alternatives.
The therapy’s potential for outpatient administration, coupled with these favorable safety metrics, contributes to what could be a distinctive competitive position. Current CAR T treatments typically mandate inpatient care and are associated with more substantial toxicity concerns.
Following the data announcement, Baird elevated its ALLO price objective from $7.00 to $9.00 while retaining its Outperform recommendation. The investment firm also boosted its probability of success projection for this therapeutic program to 70%.
<blockquote>
 “The limited dataset size of 12 treated patients should generate enthusiasm,” Baird wrote, acknowledging the early-stage nature of the readout while flagging the initial results as a positive signal for the commercial profile in the first-line setting.
</blockquote>
<h2 id="looking-forward">Looking Forward</h2>
The ALPHA3 clinical study is recruiting approximately 220 participants across more than 60 clinical sites. Efficacy endpoints continue to remain blinded currently, and the available dataset remains relatively limited. These preliminary figures will require validation as additional trial data matures.
Scheduled interim event-free survival analyses are anticipated in 2027, with complete primary results projected for 2028. Favorable outcomes from these assessments could potentially support a future biologics license application submission.
Additional Wall Street analysts are monitoring developments closely. <a href="https://coincentral.com/is-starbucks-sbux-finally-turning-the-corner-jefferies-thinks-maybe/" rel="noopener noreferrer nofollow">Jefferies</a> recently launched coverage on ALLO with a Buy recommendation and a $6.00 price objective, while Citizens maintained its Market Outperform stance with a $5.00 target price.
ALLO shares reached $3.87 on April 13, advancing from the previous session’s close of $2.91. The equity has gained approximately 99% year-to-date and is currently trading near its 52-week peak. InvestingPro analysis indicates the stock is presently valued above its calculated fair value, though the biotechnology company maintains a balance sheet with cash holdings exceeding debt obligations.
The post <a href="https://blockonomi.com/allogene-therapeutics-allo-stock-soars-41-following-breakthrough-car-t-cell-trial-results/" rel="noopener noreferrer nofollow">Allogene Therapeutics (ALLO) Stock Soars 41% Following Breakthrough CAR T-Cell Trial Results</a> appeared first on <a href="https://blockonomi.com" rel="noopener noreferrer nofollow">Blockonomi</a>.

Allogene Therapeutics (ALLO) Stock Soars 41% Following Breakthrough CAR T-Cell Trial Results

Table of Contents

Blockonomi

Other articles published on Apr 13, 2026

Join our free newsletter for daily crypto updates!